Tech Company Financing Transactions
Concentric Analgesics Funding Round
Concentric Analgesics, based in San Francisco, scored $76 million in investment from Oracle, Cowen Capital Partners and Kern Whelan Capital.
Transaction Overview
Company Name
Announced On
5/23/2019
Transaction Type
Venture Equity
Amount
$76,000,000
Round
Series B
Investors
Proceeds Purpose
Concentric intends to use the proceeds from the financing to advance its lead product candidate, CA-008, into late stage clinical trials targeting the post-surgical market.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
101 California St. 1210
San Francisco, CA 94111
USA
San Francisco, CA 94111
USA
Phone
Website
Email Address
Overview
Concentric Analgesics, Inc. is a private, biotechnology company focused on discovering and developing novel, non-opioid therapeutics for the management of acute and chronic pain. Founded in 2014 and based in San Francisco, California, Concentric is developing a portfolio of non-opioid therapeutics that provide long-lasting pain relief after a single local administration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Frank Bellizzi
Chief Scientific Officer
Craig Husfeld
President
John Donovan
VP - Bus. Development
Susan Kramer
VP - Operations
Sue Wollowitz
Browse more venture capital transactions:
Prev: 5/23/2019: Locana venture capital transaction
Next: 5/23/2019: AppHarvest venture capital transaction
Share this article
About Our VC Transactions Data
We report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs